Introductory remarks

Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

Session 1 – Keynote presentation

• Optimising multinational clinical trials with antimicrobials, the key role of clinical trial networks
  • David Paterson, National University of Singapore & ADVANCE-ID

Session 2 – Drug discovery: new targets and new chemistry

Chair: Lori Snyder, Professor of Microbiology and Genomics, Kingston University London

• Old drugs, new connections: a systems view on antimicrobial resistance
  • Elisabetta Cacace, ETH Zurich
• Discovery of lariocidin: A knotty solution to antimicrobial resistance
  • Manoj Jangra, McMaster University
• Cyclic-di-GMP signaling as a target for biofilm control
  • Tim Tolker-Nielsen, University of Copenhagen

Session 3 – Preclinical antimicrobial development

Chair: Ronan McCarthy, Professor in Microbial Biofilms, University of Southampton

• Lysin Biotherapeutics: From Microbiome Modification to the Clearance of Severe Invasive Infection
  • Assaf Raz, Precisio Biotix Therapeutics
• Extracellular strategies: Anti-virulence therapies to halt chronic multidrug resistant infections
  • Christopher Jonkergouw, Arivin Therapeutics

Session 4 – Panel discussion: Equitable TB care: Closing the treatment gap for vulnerable population

Chair: Methee Chayakulkeeree, Professor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

• Panel
  • Nick Paton, National University of Singapore & The London School of Hygiene and Tropical Medicine
  • Chen-Yuan Chiang, Wan Fang Hospital, Taipei Medical University
  • Wanatpreeya Phongsamart, Siriraj Hospital, Mahidol University

Day one closing remarks

François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

Introductory remarks

François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

Session 5 – Clinical development and use of new agents

Chair: Abi Manesh, ADVANCE ID & NUS Saw Swee Hock School of Public Health

• Novel antibiotic combination for A. baumannii
  • Glenn Dale, BioVersys
• Chlamydia trachomatis vaccine development
  • Alvaro Borges, Statens Serum Institut
• The clinical development of gepotidacin: a novel oral antibiotic for the treatment of uncomplicated UTI
  • Jeremy Dennison, GSK

Session 6 – Oral poster presentations

Chair: Chung The Hao, Senior Research Fellow, ADVANCE-ID & National University of Singapore

• Investigating the aetiology and contribution of antimicrobial-resistant infections to illness and death among hospitalised adults with advanced HIV disease: observations from a retrospective cohort in South Africa
  • Emily Prendergast, University of the Witwatersrand
• Co-Resistance mapping of Ciprofloxacin and Ceftriaxone in Uropathogenic E. coli and Klebsiella
  • Hena Sojitra, Krishna School of Science
• Post-fluoroquinolone treatment molecular events and nutrient availability modulate Staphylococcus aureus antibiotic persistence
  • Nisha Mahey, UConn Health
• Reviving the activity of antibacterial agents against Gram negative bacteria
  • Elissar Mansour, University of Sydney
• Widespread Colonization by the Candida parapsilosis species complex in Spanish Critical Care Units
  • Laura Alguacil Cuéllar, Instituto de Salud Carlos III

Session 7 – From womb to world: Antimicrobial innovation for pregnancy and childhood

Chair: Esther Bettiol, Associate Lead, Medical Sciences, GARDP

• Crossing the placenta: The case for including pregnant women in antimicrobial trials
  • Sumati Nambiar, Johnson and Johnson
• STIs and silent harm: Maternal infections and neonatal sepsis
  • Teodora Elvira C. Wi, World Health Organization
• Tiny doses, big stakes: Designing antibiotics for neonates and children
  • Julia Bielicki, University Children’s Hospital Basel & City St George’s, University of London 

Session 8 – Panel discussion: Access isn’t the end, it’s the beginning: Reclaiming the purpose of antibiotic innovation 

Chair: Jovana Albig, Associate Medical Lead, Sexually Transmitted Infections (STIs), GARDP

• Panel
• • Manica Balasegaram, GARDP
  • Anita Kotwani, University of Delhi
  • Jeffrey Smith, Unitaid

Closing remarks

Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary